1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
653420110DA1004BE85257425005700EC
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/pharmaceutical-competitive-intelligence-excellence-optimizing-data-collection-within-approved-guidelines?opendocument
18
19opendocument
2035.175.191.72
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services

Pharmaceutical Competitive Intelligence Excellence: Optimizing Data Collection within Approved Guidelines

ID: PSM-226


Features:

28 Data Graphics

115 Metrics

44 Narratives


Pages: 56


Published: Pre-2014


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • VIEW TOC AND LIST OF EXHIBITS

STUDY OVERVIEW


This benchmarking study was conducted to understand how U.S. pharmaceutical and biotechnology organizations can optimize their CI operations while working within defined guidelines. The research examined a number of areas, including CI information sources and what is being collected. In addition, the study looked at how CI groups work with legal groups to develop standard operating procedures for data collection that are in the best interests of the organization as a whole and to maximize the CI department’s ability to deliver results. Managers and executives in CI and CI-related groups can use this report to compare critical elements of their operations with those of leading firms.

KEY TOPICS

  • Optimizing Data Collection - People, Processes & Practices
  • Development & Examples of CI Guidelines
  • Managing Expectations
  • Rapid Response Teams
  • Building a Successful CI Function

KEY METRICS

  • Total Number of Marketed Brands Supported
  • Number of Blockbuster Brands Supported
  • Number of Pipeline Products Supported
  • Number of Competitive Intelligence Full-Time Employees (FTEs)
  • Effectiveness of Primary and Secondary Data Sources
  • Effectiveness of Internal and External CI Data Collection Sources
  • Effectiveness of Sources for Types of Information
  • Formal Policies/Guidelines Governing CI Performance and Scope
  • Functions Responsible for Guidelines Governing CI Operations
  • Information Included in CI Guidelines
  • Assessment of Guideline Impact on CI Function Productivity
  • CI Guidelines Training
  • CI Activities Ethical Assessments
  • Rapid Response Team Utilization

METHODOLOGY

This research was based on benchmark survey data from 24 executives from both large and small pharmaceutical and biotechnology companies. Executives from eight companies participated in the interview portion of the research.

Industries Profiled:
Biotech; Pharmaceutical; Health Care; Medical Device; Diagnostic


Companies Profiled:
Alcon Laboratories; Sanofi-aventis; Takeda Pharmaceuticals; Pfizer; Roche; Merck; Eli Lilly; Baxter Healthcare; Amgen; Vertex Pharmaceuticals; Theratechnologies; Stiefel; Shire; PDL; King Pharmaceuticals; Indegene Lifesystems; Human Genome Sciences; Ethicon Endo-Surgery Inc.; EMD Serono; ConjuChem Biotechnologies; Centocor; Inc.; Biogen Idec


Table of Contents

Table of Contents 2
Research Overview 3
Benchmark Class 4
Study Perspective 5
Scope of Benchmark Class 6
Definitions 7
Key Findings and Insights 8
Data Sources 12
Multiple Sources are Vital to Effective CI 13
Must-Haves and Effective Secondary Sources 14
Small Pharma Relies Heavily on Secondary Sources 15
Large Pharma Rates Primary about Secondary Sources 16
Optimizing Data Collection – People 17
People and Processes are Keys to Optimizing Data Collection 18
Profile of the Best CI Employee: Spotlight 19
Optimizing Data Collection – Processes 20
Tap Internal Sources First 21
Vendors Collect Majority of Primary CI Data 22
Most Small Pharma Employ Primary CI Research Vendors 23
Large Pharma Outsource Primary CI Research to Vendors 24
Holding Vendors to Strict Standards 25
Vendors Say They Do Not Misrepresent 26
Involve Legal to Decrease Risk 27
Optimizing Data Collection – Practices 28
Employees across Functions Gather Data Points 29
Rich Conversations Stem from Effective Elicitation 30
Take the Team Approach at Conferences 31
Information about Pipeline Products is Sought and Valued more highly 32
Corporate Strategy Proves to be Useful Data Point 33
Development and Examples of CI Guidelines 34
Best Practices for Developing CI Guidelines 35
Formal and Informal Policies Govern CI Operations 36
Guidelines Encompass Ethics Code, SCIP Policies & Laws 37
CI Guidelines Include Specific Policies & Procedures 38
Prescribed Policies Govern Primary Data Collection 39
General versus Prescribed CI Policies: Spotlight 40
Legal Creates Guidelines for Small Pharma 41
Legal and CI Work Collaboratively in Large Pharma 42
Creating CI Guidelines with Legal: Spotlight 43
CI Guidelines Enable Success 44
Train CI & Non-CI Employees on Guidelines 45
Effectively Train on the Guidelines: Spotlight 46
Executives Show Limited Support for Risky CI Practices 47
Managing Expectations 48
Manage Expectations up Front 49
Educate the Requestor and Protect the Company 50
Rapid Response Team 51
CI Plays Pivotal Role in Rapid Response Situations 52
Building a Successful CI Function 53
CI Executives Advise Emerging CI Functions to Evolve 54
About Best Practices, LLC 55